-
- ..
.. ( ) .. ( ) .. () .. .. .. .. .. . .. .. .. .. .. .. ..
i
. (, ) .. () .. (-) .. (-) .. (-) .. () .. () .. (-)
:,
76018 .-,. , 2
: (03422) 3-15-29, 2-23-01
(03422) 2-42-95E-mal:[email protected]
-
11 27.11.2012 .
-
7296 14.05.2003
'
-
- 1994
19 - 4 - 2012
'
" " 17.12.2012 .
60/88 1/2 - 16 . . . 200
-
.
,
. 2361 05.12.2005 .76018, .-,
. , 2. , ( 10.11.2010 , 1-05/7)
- , 2012 , 2012
-
C O N T E N T S
- 5 -
- 9 -
- 11 -
- 14 -
- 16 -
- 20 -
- 23 -
- 27 -
- 29 -
- 32 -
- 34 -
- 36 -
- 39 -
- 42 -
- 44 -
- 47 -
- 49 -
- 52 -
- 55 -
.., .. - : .. - ..o - , - .. - c-fos - .., .., .. .. - .., .. ,
20- .., .. - .. - ., ..- , - .. - L-() .. - 0 .., .., .. - .., ..,
.., .., .., .., .. , - .. -
.. - . ., . . - .. - -- .., ., .. -
PROBLEM ARTICLESMatejko G.B., Matvisiv M.V.Viral Hepatitis B and
C as Maternal-Fetal Infections: Dis-cussions and Unresolved Issues
of the ProblemORIGINAL RESEARCHAtamanchuk O.V.Morphofunctional
Changes of the Tongue in ExperimentalDiabetes MellitusBobrova
I.A.Concentration of Circulatory Immune Complexes in Patients
withChronic Hepatitis C Complicated by
Cytokine-AssociatedThyreopathyBulyk R.Ye.The Influence of Melatonin
on the Activity of the C-Fos Geneof Early Response in the Subnuclei
of the ParaventricularNucleus of the Hypothalamus Under the
Conditions of StressVerbovska R.I., Rozhko M.M., Divnych
T.Ya.Adhesive Agents Influence on the Oral Tissues in Patientswith
Complete Laminar DenturesVovk Z.V.Manifestations of the Anemic
Syndrome in Children withMalignant TumorsGamorak G.P., Kutsyk
R.V.Bifidumbacterin Efficiency in the Recovery of Qualitative
andQuantitative Composition of Cavity and Mucous Microflora ofthe
Colon and Distal Part of the Small Intestine in Animals
after20-Days Exposion to Skin Application of Itaconic
AcidGerasymchuk V.R., Gryb V.A.Rehabilitation of Patients in the
Early Restorative Period ofIschemic StrokeGrizodub
D.V.Investigation of Cytotoxicity of Dental Alginate Materials
Yemelyanov D.V., Galchinska V.Yu.Clinical and Immunological
Changes of Periodontal Tissuein Patients with Coronary Artery
Disease, who Take Ace-tylsalicylic AcidZozuliak N.V.Protection of
Endothelium in Patients with Stable AnginaFC III with Concomitant
Hypertension and its Correctionby Using of Nitric Oxide Donator
L-Arginine and Metabol-ic Drug MexicorKozoviy R.V.Calculation of
Odds Ratio of Longevity in PrecarpathianRegion by System of
Antigens of Blood Group AB0 and Rhrysa V.M., Hodos V.., Krysa
B.V.Ambulatory Foam Scleroobliteration and Endovasal
LaserCoagulation of Helpless Perforator Veins Under
UltrasonicControlKupnovytska .G., lymenk V.., Dzvinatska
.F.,Sapatyi .L., Dron L.., Romanyshyn N..,Vvcharenko .P.Comparative
Efficacy of Isovaltrianic Acids Drugs in Pa-tients with
Hypertensive Disease Combined with Stable An-gina PectorisLytvynets
L.Ya.Assessment of Immunological Disorders in the Genesis
ofBronchial Asthma in Children with Different Degree of
Con-trolLisnyanska I.S.Modern Aspects of Treatment of Patients with
ChronicPyelonephritisatviykiv .I., Gerelyuk V.I.Clinical Status of
the Periodontal Tissues in Patients withChronic Generalized
Periodontitis against the Backgraundof Systemic Antibiotic Therapy
of Concomitant PathologyMeretskyy V.M.State of Lipoperoxidation and
System of Antioxidant Protectionin the Liver and Kidneys of Animals
with Traumatic Brain Inju-ries against the Background of
Experimental Diabetes MellitusMishchenko L.A., Svyshchenko E.P.,
Bezrodnyi V.B.ffect of Antihypertensive Medication on
Proinflammatoryand Metabolic Cardiovascular Risk Factors in
Hyperten-sive Patients
-
- 58 -
- 61 -
- 63 -
- 65 -
- 68 -
- 70 -
- 72 -
- 75 -
- 78 -
- 80 -
- 83 -
- 86 -
- 88 -
- 89 -
- 91 -
- 94 -
- 96 -
- 99 -
- 100 -
.. - 14 - .., .., .. - .., .. , ..- .., .. .. .. .. -- .. - .. -
- .. - - .. .., .., - .., .., .., .., .. - .., .., .., .., .., .. :
.., .., .., .., .. - .., .., .. : , . ,. . . .. --- - .., .. --
Pokotylo P..The Ultrastructural Research of the Kidney
Filtration Barrieron the 14 Day of the Streptozotocininduced
Diabetes Melli-tus of the RatPrytula V.P., Silchenko M.I., Kurtash
..Protective Colostomy and Anorectal Malformations in
Chil-drenRozhko-Hunczak O.M., Nespryadko V.P.Features of
Preprosthodontical Treatment of Children Liv-ing in Adverse
Environmental ConditionsRomanukha V.V.Clinical and Pathogenetic
Paculiarities of Combined Courseof Chronic Pancreatitis with
Metabolic SyndromeSeredyuk N.., Luchko O.R.Markers of Systemic
Inflammation in Patients with ChronicPyelonephritis and Arterial
HypertensionSynoverska O..Synthetic Endothelial Function in
Children with Heart Micro-abnormalitiesSikoryn
Ya.Ya.Pathomorphological and Morphometric Features of LungVessels
in Newborns with Antenatal Associated Infec-tionsChuyko
M.M.Prognostic Significance of Changes in Certain Parametersof
Acid-Base Status on the Probability of IntraventricularHemorrhage
in Premature Newborns
Sheremeta L.M.Safety and Possible Risks in Use of Dermatologic
Medica-tionsShorikov Ye.I.Diagnostic Value of Some Indexes of
Thrombocyte and Plas-mic Hemostasis and Lipid Spectrum of Blood in
Patientswith Arterial Hypertension at Presence of
AtheroscleroticInjury of CarotidsShorikova D.V.The Dinamics of
Indexes of Cerebral Circulation in Patientswith Arterial
Hypertension and Stable Angina after Long-Term Therapy with
Lerkanidipine and BisoprololYusypchuk U.V.The Results of Estimation
of Antihypertensive Therapy ofAntagonist of Calcium Channels of
Semlopin in Patientswith HyperpiesisMEDICAL PRACTICE NOTESGayova
I.M., Zuban A.B., Kulynych-Miskiv M.O.,Korzh G.Z., Kostrytska I.M.,
Bondarenko T.Y.,Ostrovskii M.M.Diagnosis of Acquired Bacterial
Focal Pneumonia in YoungPatients at Prehospital StageGlushko L.V.,
Fedorov S.V.,Verbovska O.S., Martyniv I.V.,Nasrallah A.H., Shalamay
M.P.Symptomatic Renovascular Hypertension: The ClinicalCaseDubas
V.I., Sulyma V.S, Kovalishin T.M., Baliyk Yu.S.,Daniv V.M.Method of
Treatment of Complicated Fractures of ForearmBones in Children by
Means of Apparatus of External FixationLECTURESOrnat S.Ya.,
Ostrovskii M.M., Verbovska O.S.Thromboembolism of the Pulmonary
Artery: Modern Clas-sification, Diagnostic Difficulties and
TreatmentStovban M.P., Ostrovskii M.M.Basic Methods of Diagnosis of
Vibration DiseaseMEDICAL EDUCATIONAndriytsiv S.S.Optimization of
Modern Approaches to Postgraduate Train-ing of Dentists Within the
Bologna Education Principles
Babliuk L.A. Ostrovskii M.M.Features of Practical Classes in
Phthisiology for the Stu-dents of Stomatological Faculty of
Ivano-Frankivsk Na-tional Medical University in the Conditions of
BolognaIntegration
-
- 102 -
- 104 -
- 105 -
- 108 -
- 112 -
- 114 -
- 115 -
- 119 -
- 122 -
- 125 -
- 126 -
- 129 -
- 134 -
- 137 -
- 140 -
- 144 -
- 147 -
- 149 -
- 153 -
- 158 -
- 160 -
- 163 -
- 166 -
.. - .. - .., .., .., .., .. --. ( 6. - 2007-2011 ) .. - .. ..
--, .. . . : .. ..
.. .., .. - -, .. - - .. .. - : .. - .. - 2 .., .., .., .. , ,
.. - - .., .. , .. Laserpitium latifolium - .., .. - .. -
Vyshyvanyuk V.Yu.The Application of Tests in the Process of
Specialists Train-ing as a Method of Preparing for the
License-IntegratedTest KrokIvanochko N.Ya.Features of Learning
Surgery by Students of Stomatologi-cal DepartmentIlnytska O.M.,
Rozhko M.M., Kosenko S.V., Pelehan L.I.,Kateriniuk V.Yu.Improvement
of Educational Process for Training of Internsof Dentistry (Report
6. Methodological Support of Educa-tional Process Efficiency During
the Period of 2007-2011Years)Kapechuk V.V.Details of Writing Case
Records in Ophthalmology by Stu-dents of Stomatological Faculty of
Ivano-Frankivsk Nation-al Medical UniversityMaksymchuk L.T.Features
of Tests Creation to Monitor the Level of Knowl-edge of
NeurologyParasyuk G.Z.The Postdiploma Stage of Practical Training
of Dentists, asan Unceparable Phase of Professional
DevelopmentReitmaer M.Yo.Integration of Ukraine into Europian
Higher Education System:Main Advantages and Disadvantages. Part II:
DisadvantagesSamotovka O.L.Quality of Biostatistics Teaching in the
Eyes of Students
Skrypnyk L.M.Advantages and Disadvantages of Distance Education
inMedicineChaplynska N.V.Method of Discussion as a Form of
Postgraduate Educationof DoctorsPUBLIC HEALTH SERVICEDetsyk O.Z.,
Karpinets I.M.Comparative Analysis of Trends in Morbidity and
Mortali-ty in Ukraine and Ivano-Frankovsk Region from
CausesAssociated with Alcohol ConsumptionZhyliaev M.M.The
Comparative Evaluation of the Medical Statistical Indi-ces before
Mature and Premature DeliverySiryk V.O.Evaluation and Necessity of
Reforming Primary MedicalCare in UkraineBOOK REVIEWSBardyak
Ye.M.Evolution of Infectious Diseases in Patients of
Oncohema-tological Profile: Analysis of the Causes and
PreventionGolotiuk V.V.Neoadjuvant Radiation Therapy in the
Combined Treatment ofPatients with Colorectal CancerGryb V.A.The
Role of the Liver Functional State in the Development
ofPolyneuropathy in Patients with Type 2 Diabetes MellitusDelva
Yu.V.,YatsyshynR.I.,Sandurska Ya.,V., Oliynyk O.I.Fibromyalgia
Modern Conceptions, Clinical Features, TreatmentZhyliak
O.V.Influence of Functional and Organic Bowel Diseases onPancreatic
Secretion Peculiar to ChildrenLitvinets-Holutyak U.Ye., Rozhko
M.M.Modern Peculiarities of Etiological Structure, Clinical
Courseand Diagnostic Criteria of Odontogenic CystsSikoryn
U.B.Biologically Active Substances Laserpitium latifolium
andCurrent State of their StudyTkachuk O.L., Shabat G.I.Choice of
the Method of Biliary Decompression During Ma-lignant Mechanical
JaundiceFedorkiv M.B.Respiratory Distress Syndrome in Acute
PancreatitisINFORMATION FOR AUTHORS
-
5 , 2012, . 19, 4
: 618.2-082+613.952+616.36-002+616.98:578.828
.., .. - : (. . . .. )-
. - ( ) -: -, , , ,.
: , , .
. (), , - - . , ( , ), [7].
, - , - -- [2,3,13]. - , , - [1].
- , TORCH- [8]. , - 18% , 3% [3]. -.
- - - [9]. - 1000 1-2 5-15 - , + [4, 7].
, - , . - , - [6, 7, 10]. , ++ [6, 10]. - , - .
- , , , -, .
, - , : , - , , ?
- , . , - , , , , , ,
, - , .
() . - (). - , : - 10%, - 70% [4].
HBsAg - 408 1989 ., - - . ( ) - HBsAg , - , . , , - -, HBsAg . -
HbsAg( - - ) . , .
, - . - , - , -, (). HB- -HBsAg HBAg, -HB, -HB , , . HBAg [5,
11,15]. , - , .
, -HBc - 10 , HBsAg, . 4-40% - [3]. HBsAg .
HBsAg -HBc . (-HBcIgM, HBeAg -) HBsAg( ) . , -HBc, , , .
-HBsAg, HBeAg, , ( ()).
-
, 2012, . 19, 4
6
[11]. HBsAg, , - (), - . HBeAg - 6 [15]. - 2,4%, HBeAg- - 5,5%,
( 8 lg /) - 7,2% [14]. , , [3, 5, 8].
. , -, , , - [8].
. - - , - [15].
. , - - . [11], , - - .
, : , , , , , .
, - -, . , .
, , , - [3, 8, 14]. .
(-), >107 / [12]. - - [12]. 32 4 100 /, - - . HBsAg- 39% 18%,
- 46% 20%. 12,5%, - 28% [12].
- . ( ) () - ( , - ). ( ) , .
, :-
106 /) - ;
- , - ;
- - .
, 3 , . , , , [4]. .
- [4, 9]. , -, (90-95%). - 10 30 . -- [4, 5].
HBsAg,HBeAg, HBV, . HBsAg , 30% (
-
7 , 2012, . 19, 4
-HCV - . , , - . -, HCV [1, 3, 13].
- , 60-80% [5]. - 3- 33,3% [5].
, - -. , . - . , - , , - , [13]. , , , - ++- [5, 6, 14]. [1, 6,
11], - 0% 41%, - 5%, - - 17%, - 3%.
: >106 /, - , +-, - , >6 -, TORCH- , , ( , ), - (), [2, 8,
11, 13].
( ) - . , [13]. [2], - [4,9].
, , , , -HCV , - 12-16 . 18 -HCV HCV, . HK HCV . HK HCV . - , -
[2, 5].
, . , , , . - , , , .
- - - . , , - . ( ) - [5].
, . - , - (-HCV) - .
. - (-, , , ) . [5], , , - .
++, . [15], - ++, , , , .
- HBsAg -HCV - 551 12.07.2010 . - -
-
, 2012, . 19, 4
8
, , , - .
1. .. : , ,
, : / .. ,.. , .. . - ., 2007. - 38 .
2. : / .. , .., .. [ .]. - .: . - 2010. - .275.
3. - / .. ,.. , .. [ .] // . -2007. - 3 (41). - . 3-10.
4. / .. -, .. , .. [ .] // . . - 2003. - 1. - . 32-34.
5. . . : , : .. . / .. . - , 2006. 176 .
6. .. - / .. , .. // . . -2001. - 2. - . 15-18.
7. .. - / .. , .. , .. // - . - 2004. - 3. - . 40-45.
8. .. /.. , .. , .. // - . - 2000. - 2. - . 4-7.
9. .. : . - /.. , .. , .. . - .: -, 2006. - . 243.
10. , - / .. , .. , .. [ .] // . - ., 2001. - . 25-28.
11. Elective caesarean section versus vaginal delivery for
prevent-ing mother to child transmission of hepatitis B virus a
systematicreview / J. Yang, X.M. Zeng, Y.L. Men [et all] // Virol.
J. - 2008. - Vol.
28, 5. - P. 100.12. Lamivudine in late pregnancy to prevent
perinatal transmis-
sion of hepatitis B virus infection: a multicentre, randomized,
double-blind, placebo-controlled study / W.M. Xu, Y.T. Cui, L. Wang
[et all ]// J. Viral. Hepat. - 2009. - Vol. 16, 2. - P. 94-103.
13. Lavanchy D. The global burden of hepatitis C / D. Lavanchy
// Liver Int - 2009. - Vol. 29. - P.74-81.
14. Perinatal transmission of hepatitis B virus: viral load
andHBEAg status are significant risk factors / E. Wiseman, M.A.
Fraser,S. Holden [et all] // Hepatology. 2009 - Vol. 48, 4. - P.
676.
15. Wang Z. Quantitative analysis of HBV DNA level and
HBeAgtiter in hepatitis B surface antigen positive mothers and
their babies:HBeAg passage through the placenta and the rate of
decay in babies /Z. Wang, J. Zhang, H. Yang [et all] // J. Med.
Virol. - 2003. - Vol. 71, 3. - P. 360-366.
.., .. - -
: .
( ) - : -, , -, , .
: , , .
Matejko G.B., Matvisiv M.V.Viral Hepatitis B and C as
Maternal-Fetal Infections: Discus-
sions and Unresolved Issues of the ProblemSummary. The analysis
of literature data on the actual problems
of hepatitis B and C (HB and HC) as the maternal-fetal
infections wereperformed: peculiarities of perinatal HB and HC in
children, risk fac-tors for the fetus infection in women with these
infections, the ways toimprove their diagnostics, treatment and
prevention .
Key words: pregnant women, newborns, hepatitis B and C.
22.10.2012 .
-
9 , 2012, . 19, 4
616.316.1:616.313]-009.85-009.614-091:611.068
.. (. . - . ..)-
. ., , , - , , . , , . .
: , .
.- (), - , , [2,7,8]. - [12]. , [9]. - - [6,11]. - , , - 12- , ,
- [1,4,5]. - [3,10], 25,0% - , , [9,11]. , - . -, - () [6,12].
- - .
30 -
250-300 , 5 - , 25 , - -- [1]. - , - - . - - . - -, - . -
[4]. - . - .
, -
. , - [6,11,12]. - --, .
. - - (. 1).
, -, , , - , .
6-8 - (. 2, ),
. 1. ( ) .
, , .: . .: 2100, 850, 350
-
, 2012, . 19, 4
10
, - (. 2 , ). , , - . , 80,0% [6,11].
6,600,25%, [4].
2 3,230,28%, 8 1,900,15% (P
-
11
, 2012, . 19, 4
3. 1- - / . . , . . , . . [ .] // . 2007. 3. .710.
4. .. - / .. // . 2011. . 2, 51. . 6061.
5. / .. , .. , .. [ .] // 2007. .5, 5. . 2326.
6. 1- / . . , . . , . . [ . ] // . 2008. 6. . 913.
7. .. - / .. , .. // . 2009. 4. . 3738.
8. - / .. , . . , . . [ . ] // . 2009. 6. .3639.
9. . . / . . , . . , . . // . 1 2010. . 37.
10. .. ( -) / . . , .. // - 2008. .38, 2. . 4246.
11. Bataineh A. A Survey of Localized Lesions of Oral Tissues:
AClinicopathological Study / Anwar Bataineh, Ziad Nawaf AL-Dwairi
//J. Contemporary Dental Practice. 2005. V.6, 3. . 198201.
12. Plasticity of the different neuropeptide-containing nerve
fibresin the tongue of the diabetic rat / Bayarchimeg Batbayar,
Tivadar Zelles,gota Vr [et al.] // J. Peripheral Nervous System.
2004. V. 9, 4. P. 215223.
.. -
.
., , , - , , . , , . .
: , .
Atamanchuk O.V.Morphofunctional Changes of the Tongue in
Experimental Di-
abetes MellitusSummary. The purpose of work was consisted in the
study of changes
in the structure of certain components of rat tongue in the case
of norm andexperimental streptozotocin diabetes mellitus. It was
established that withthe increase of supervision term the
progressive decrease of diameter andheight, in the first place, the
filiform and fungiform papillae, taste bulbpopes expansion,
decrease of the regeneration potential of epithelium oc-cur in the
mucous membrane of tongue. It was observeb the
segmentalbemuclination in the nervous fibres and in the muscles of
tongue weve gotthe fibrolis, cytololysis and vacuole dystrophy of
some muscular fibrs.The possible mechanisms of structural changes
and their role in the originof some clinical manifestatis of
diabetes mellitus come into question.
Key words: tongue, diabetes mellitus.
29.10.2012 .
616.36-002.612.017.1.
..o , ... , .
. - , - . 294 , 39 . .
: , , , .
. [5]. V , - [8]. , , , [2, 12, 13, 14].
[6, 7]. - , - [9, 10, 11]. ,
[3]. .. [11],
, - , - 1,6 . : - (11S-19S) (
-
, 2012, . 19, 4
12
, .
294 . -
- (HCV) .
HCV , (1), 165 (56,12%), 2 HCV 12 (4,08%), 3 107 (36,39%). 6
(2,04%) HCV , 4 (1,36%) 1 + 2 3.
- Flexor Jun-ior () - Human().
- Sanofi () - CIC-C3D BCM Diagnostics.
() 39 () (- ) , , .
- ( SPSS, 17 Microsoft Office Excel 2007).
,
-, . - : 15,551,03mol/l 3,530,30 U . - , : - -100,039,37 U/l, -
- 58,266,0 U/l. -- 67,0210,8 U/l (N 11-61U/l).
- (61,22%) -
(38,78%) . 1 V 48 , 24 .
( -) (.1). - 75,3914,32 IU/ml, 18,85% (46 ). 3 , 68,6319,12
IU/ml. , , - - 77,9522,19 IU/ml ( > 90IU/ml 21 =13,82%). -
69,4518,73 IU/ml ( 10 = 14,71% ).
3 (
-
13
, 2012, . 19, 4
>0,05(.3).
, - - 3 (
-
, 2012, . 19, 4
14
Bobrova I.A.Concentration of Circulatory Immune Complexes in
Patients with
Chronic Hepatitis C Complicated by Cytokine-Associated
ThyreopathySummary. Koncentration of circulatory immune complexes
was stud-
ied by IFA-analysis at patients with chronic hepatitis C wich
complicatedcytokine-induced thyropathy.
Combined antiviral therapy got 294 patients, among them 39
patients
had developing thyropathy. The levels of immune complexes
patients withthyroid pathology exceeded levels omparison group at
all control therapyterms without convincing increasing in the
treatment process.
Key words: circulatory immune complexes, chronic hepatitis C,
cy-tokine-induced thyropathy, antiviral treatment.
24.09.2012 .
612.826.4:612.017.2
.. c-fos , (. . . ..)
. c-fos () ( ). c-Fos , , . . , c-Fos .
: -fos, c-fos, - , , -.
. - () , , -- - - [3, 5].
- (, ) - , - , - [4,10]. , - , -- (). - , , () . - . -fos , - -
.
, , [2, 8]. () - -fos [6,7,11]. - -Fos [5, 9]. - , , - [1,
4].
- , - ,
. -
c-fos - .
36 -
150180 . - . - , , , ( ).
() (- 12 , LD, - 08.00 20.00 , 500 ). - (LL, ). , , 19.00
(Sigma, , 99,5%) 0,5 /, 1,0 (0,9% - ).
14.00 02.00 , - (40,0 /, -). 10 % (0.1 , pH 7.2) 20 . - . - - (,
1986).
c-Fos . ( IGG) c-Fos (Sigma-Aldrich, ). - , , (FITC;
Sig-ma-Aldrich, ).
c-Fos VIDAS-386 (KontronElektronik, ) . 370390 420450 - . 8-
CCD-- COHU-4922 (COHU Inc., ) VIDAS-386. - , FITC - . 256
-
15
, 2012, . 19, 4
. VIDAS-2.5(Kontron Elektronik, ). , - ( - ). , (S
S
, 2). -
(D
D
0) -
, c-Fos - , K
=lg (D
/D
0) C
=K
iS
( . .) . , , - c-Fos .
- .
VIDAS-2.5 (KontronElektronik, ) EXCEL-2003 (Microsoft Corp., ).
, . , - S
S
K
i C
, 120153 . , c-Fos-
. ( ) - 1 2 . (t). , P
-
, 2012, . 19, 4
16
c-Fos - , c-Fos .
2. - , , , , , 26,781,690 2.
-
, .
1. .. :
/ . . - // . 2007. 1 (19). .4-7.
2. .. - / .. , .. -, . . // . . 2005. 4. .38-45.
3. . . - / .. , . . // . 1996. . 110, 4. . 3741.
4. . . - / . . , . . // . . 2003. .34, 4. .37-53.
5. - - / . . , . . , . . [ .] // . . . 2006. . 3, 2.
.120123.
6. Arendt J. Melatonin: characteristics, concerns, and prospects
/J.Arendt // J. Biol. Rhythms. 2005. Vol.20. P.291-303.
7. Ekmekcioglu C. Melatonin receptors in humans: biological
roleand clinical relevance / C. Ekmekcioglu // Biomed.
Pharmacother. 2006. Vol.60, N3. P.97-108.
8. Decker M.J. Paradoxical sleep suppresses immediate early
geneexpression in the rodent suprachiasmatic nuclei / M.J. Decker,
D.B.Rye,S.Y. Lee // Front. Neurol. 2010. Vol.22. N.1. P.122.
9. Golombek D.A. Neurochemistry of mammalian entrainment:Signal
transduction pathways in the suprachiasmatic nuclei /
D.A.Golombek, G.A.Ferreyra, M.E Katz // Biol. Rhythm Res. 2000.
Vol.31, N1. P.56-70.
10. Reiter R.J. The photoperiod, circadian regulation and
chrono-disruption: the requisite interplay between the
suprachiasmatic nucleiand the pineal and gut melatonin / R.J.
Reiter, S. Rosales-Corral, A.Coto-Montes // J Physiol Pharmacol.
2011. Vol. 62. N3. P.269274.
11. Schwartz W.J. Circadian rhythms: a tale of two nuclei /
W.J.Schwartz // Curr. Biol. 2009. Vol. 19, N.11. P.460462.
. .
c-fos -
. c-fos - () - ( ). c-Fos , - . . - , c-Fos .
: -fos, c-Fos, , , .
Bulyk R.Ye.The Influence of Melatonin on the Activity of the
C-Fos Gene
of Early Response in the Subnuclei of the Paraventricular
Nu-cleus of the Hypothalamus Under the Conditions of Stress
Summary. The influence of melatonin on the state of the gene
ofan early functional activity-c-fos in the subnuclei of the
paraventricu-lar nucleus (PVN) of the rat hypothalamus at different
intervals of thecircadian period (in the day-time and night) was
studied. The expres-sion of the product of this gene the c-Fos
protein in animals keptunder normal conditions of alternating
lighting and darkness demon-strated a rather legible circadian
pattern. A light stress results in markeddesynchronosis. Melatonin
injections normalized the diurnal rhythmof the index of the area of
the material against a background of perma-nent lighting,
immunoreactive to c-Fos in PVN subnuclei of the
rathypothalamus.
Key words: c-fos gene, immunospecific c-Fos protein,
hypotha-lamic paraventricular nucleus, permanent lighting,
melatonin.
27.08.2012 .
: 616.31+616.314-77+615.454.1
.., .., .. (. . . ..) ,,-
. 120 - , : - . - - . - , . (-, ) , - . , .
0,5 . ,
3- , -.
: , , .
. 57,5 1000 [1].
-
-
17
, 2012, . 19, 4
[2]. , 26% -
, 4- . 37% . , - 3 - 85,2% [3].
- : , , , , , -- -, - , [4].
. - . - : - -, ( ); - ; ; - ; - [5].
[6]. - , - . - , : , , . : Corega, Presi-dent, Lacalut. . .
.
120 30-70 - . -, - . , , -. Statistica 6.0.
: - 50,0% 47,22% , , 60,0% 40,0% , ; 28,27% - , 20,0%, ; -
52,57% - , 60,0% , .
. , - ,- , , - .
- (.1). 35,09% 33,96% , 15,0% , 33,3% , .22,81% - 28,30% , ,
15,0% , , - . 21,05% - ,13,21% , - 14,04% ,33,33% , . 30,0% - 7,55%
, , 30,0% 33,33% , ,
1.
-
%
-
-,%
-
%
-
-,%
-
%
-
-,%
-
%
-
-,%
20 35,09* [26,43; 50,49]
18 33,96 [25,23; 49,95]
3 15,00* [9,20; 40,01]
2 33,33 [35,18; 95,51]
13 22,81 [15,49; 36,86]
15 28,30 [20,12; 43,73]
3 15,00 [9,20; 40,01]
0 0 [12,50; 51,53]
12 21,05 [14,02; 34,83]
7 13,21 [7,69; 25,98]
6 30,00 [20,93; 58,28]
2 33,33 [35,18; 95,51]
0 0 [0,21; 6,53]
0 0 [0,24; 7,00]
1 5,00* [3,24; 25,97]
0 0 [12,50; 51,53]
0 0 [0,21; 6,53]
0 0 [0,24; 7,00]
1 5,00* [3,24; 25,97]
0 0 [12,50; 51,53]
8 14,04 [8,39; 26,42]
4 7,55* [3,73; 18,61]
6 30,00 [20,93; 58,28]
2 33,33*
[35,18; 95,51]
4 7,02 [3,42; 17,36]
9 16,98 [10,59; 30,62]
0 0 [1,55; 17,66]
0 0 [12,50; 51,53]
: * - (0,05) ; ** - (0,01) ; *** - - (0,001)
-
, 2012, . 19, 4
18
- (.1). ,
0,5 1 , -, , 1%. - 3 , - 8%, 5%, 6%, 5% .
- 23,68% , , - . 37,50% , 33,33% , , . 55,26% 81,82% , -, 25,0%
33,33% , . 21,05% 18,18% , , 31,25% 33,33% , (.2).
, - 1- - 3%, 1-2% (. 1). 3- 5% , 1%.
- , 1- 3% - . 3 9% (. 2).
, , . 25,0% - - 81,82% , , 37,04% 33,33% , , - . 68,75% - 18,18%
, , 62,9% 67,0% , .
, - ,
2.
-
%
-
-, %
-
%
-
-,%
-
%
-
-,%
-
%
-
-,%
8 21,05 [13,47; 38,74]
4 18,18 [11,31; 42,52]
5 31,25 [22,54; 63,97]
2 33,33 [35,18; 95,51]
9 23,68 [15,63; 41,85]
0 0 [1,30; 16,16]
6 37,50 [28,07; 70,94]
2 33,33** [35,18; 95,51]
21 55,26* [45,24; 75,39]
18 81,82** [74,94; 99,15]
4 25,00* [17,35; 56,66]
2 33,33** [35,18; 95,51]
0 0 [0,46; 9,65]
0 0 [1,30; 16,16]
1 6,25 [4,65; 31,86]
0 0 [12,50; 51,53]
: * - (0,05) -; ** - (0,01) ; *** - (0,001)
3.
-
%
-
-,%
-
%
-
-,%
-
%
-
-,%
-
%
-
-,%
11 19,30 [12,56; 32,77]
14 38,89 [29,05; 59,40]
3 10,34 [5,57; 28,37]
4 36,36 [29,10; 78,55]
- 8 14,04 [8,39; 26,42]
4 11,11 [5,99; 26,90]
5 17,24 [10,39; 37,34]
2 18,18 [14,36; 56,92]
0 0 [0,21; 6,53]
0 0 [0,51; 10,16]
1 0,03 [1,79; 18,35]
0 0 [4,52; 30,40]
29 50,88 [41,68; 66,81]
18 50,00 [39,81; 70,86]
10 34,48 [24,75; 57,46]
4 36,36 [29,10; 78,55]
0 0 [0,21; 6,53]
0 0 [0,51; 10,16]
1 3,45 [1,79; 18,35]
0 0 [4,52; 30,40]
9 0 [9,75; 28,57]
0 0 [0,51; 10,16]
7 0,24 [15,82; 45,71]
1 9,09* [8,50; 44,61]
0 0 [0,21; 6,53]
0 0 [0,51; 10,16]
1 3,45 [1,79; 18,35]
0 0 [4,52; 30,40]
0 0 [0,21; 6,53]
0 0 [0,51; 10,16]
1 3,45 [1,79; 18,35]
0 0 [4,52; 30,40]
: * - (0,05) ; ** - - (0,01) ; *** - (0,001)
-
19
, 2012, . 19, 4
.1. C ,
00,5
11,5
22,5
33,5
44,5
55,5
%
0,5 1 3 3
0123456789
10 %
0,5 1 3 3 .2. C ,
0 0,5 1 1,5 2 2,5 3 3,5 4 4,5 5 5,5 6 6,5%
-
0,5 1 3 3 .3.
,
0 1 2 3 4 5 6 7 8 9 10%
-
0,5 1 3 3
.4. ,
50,88% 50,0% , , 34,48% 36,36% (. 3). - 19,30% - - 38,89% , ,
10,34% 36,36% , - -.
, 1- , (. 3).
- - , - 3 , 3% -, 6%, 5% (.3).
- -, - 3 7% , 8- 9% (. 4).
70,27% 77,27% , , 33,33% 66,67% - ,
. 29,73% 22,73% , , 66,67% 33,33% , .
-
, 2012, . 19, 4
20
7,50% 12,0% , - . 17,50% - 24,0% , - , 4,17% 16,67% , -.
1. -
, ( 35,09%, 28,30%).
2. 55,26% 81,82% , .
3. 0,5 -, - 1-2% .
4. -, 3- , - 9%.
, - .
1. .. ,
/ .. , .., .. // . - 2002. - 6. .107-110.
2. .., .., .. // . 2010. .202-205.
3. .. :.... .- .- 2002. 22.
4. .. -, /.., .. // . 2004. - 8. .180-181.
5. .. , // ..- 1997.- 4. .16-20.
6. : // . 2000. - 1. .33-34.
Verbovska R.I., Rozhko M.M., Divnych T.Ya.Adhesive Agents
Influence on the Oral Tissues in Patients with
Complete Laminar DenturesSummary. 120 patients with complete
laminar dentures have been
examined and divided into groups: patients that used adhesive
agentsand those that didnt use them. Complete edentia leads to
local andgeneral complications. The influence of dentures fixation
creams onthe oral mucosa depending upon their life time is worth
investigating.Discomfort in the oral cavity (dry mouth, tension) is
more common inthose patients with complete laminar dentures that
use creams to im-prove fixation. While examining the oral mucosa it
has been found outthat patients using fixing creams suffer more
often from inflammatoryconditions.
Key words: complete laminar dentures, oral mucosa,
adhesivecreams.
15.10.2012 .
371.315+616-071+546.72+613.95
.. -
. - . , - . - . , , . , . - , - . -. . - .
: , , ,.
. -, , . - - .
, -, , - , ., - -. , , , . ,, , , , - [1, 2, 5].
() - , : - (-1, , -) , , [3, 4]. 120 80-90 . , - , - . - ,
-
21
, 2012, . 19, 4
- - [4, 6].
- - .
- , - - , - - - - .
99 -
, . -- 2004 2011 . 65 - 34 1 9 14 7 ( 6 3 ).
: 54 , , : 50 ; 33 , ; 12 , .
- . -: , , , ( , ), , - (), ().
-.
, -
, , . , - , -, (. 1).
, , ( 92,6%, 93,9%, 83%). - - 77,7% 52% 52% . - (75,0% 48,1%
36,4% ). : 81,5% - 84,8% - , 3,3 (25,0%) .
. , - (88,9%). , - (72,2%). - - . -
(87,9%). , 63,6% , - , - , , , - . - .
.
(77,7% 90,0% ) .
(pica chlorotica) , , , 81,5% 63,6% (). , - , - - . 61% ,
(30,3%) . ( ) - . , - .
- - (. 2). , , .
, , (
-
, 2012, . 19, 4
22
-. , . . , , (). - (91,030,79) , . - (-), - . -
[(27,110,93)109/], (
-
23
, 2012, . 19, 4
: 615.24+616.34-008.8+616.345+616.341+616-092.9+615.262
.., .. , 20- , , (. . - ... ..) -
. 15 - , - -, , , Candida. , Bifidobacterium, Bacteroides,
Enterococ-cus, Peptostreptococcus ; - , - . - , 20- , , , , - ,
.
: , , , .
. , . . [1]. - - Bifidobacterium . - , . [3,4].
15 - . [2,5].
- Bifido-bacterium, , , - , [1].
: , - , - 20- 20 /2.
30
200-220 , [3,4,5]. - ( , .).
-, -, , . 20- 15 .
- - . 10 - .
- 15 20- - 20 /2 - 1.
, 20- 20 /2 - , .
(107/) 15 - Bifidobacterium, Eubacte-rium, Lactobacillus . , (E.
coli Hly+) (Klebsiella, Edwardsiel-la) Candida. , - , -
Lactobacillus,Peptostreptococcus, Eubacterium, Bacteroides, - , ,
.
, - 15 20- - 20 /2 (. 2.)
, 20- 20 /2, - - - Bifidobacterium, Bacteroides, Lactobacillus,
Peptostreptococ-cus, Enterococcus Escherichia. 15 - (Lac-tobacillus
.) - - (20-30%) -
-
, 2012, . 19, 4
24
Proteus, Pantotea. - 30-60 .
, 20- - 20 /2 3.
, - - (Klebsiella, Ed-wardsiella) . Bifidobacterium,
Lac-tobacillus, Bacteroides, Peptostreptococcus, Enterococcus. ( )
-
, , -, . Clostridium.
- - , 20 - 20 /2 4.
20 20/2 (50-60%) , ( ). - ( 34,5%), ( 23,5%), ( 44,2%), (
36,2%). - - , , -
1. 15 20-
20 /2
(n=10) (n=10) 15
(n=10) (lg
/) m
(lg
/) m
(lg /) m
1
1. Bifidobacterium 8,970,30 90,0 104,4 6,100,33 100,0 93,0 <
0,01 7,300,23 100,0 108,3 < 0,05 < 0,01 Lactobacillus
9,850,32 90,0 115 6,000,25 100,0 91,5 < 0,01 6,630,21 80,0 66,8
< 0,01 < 0,05 Eubacterium 5,370,33 30,0 57,1 4,790,06 80,0
21,9 > 0,05 5,540,07 30,0 24,7 > 0,05 < 0,05 Bacteroides
9,720,27 100,0 126,5 8,050,18 100,0 122,7 < 0,01 8,490,19 100,0
126 < 0,05 > 0,05 Peptococcus 8,78 10,0 11,7 7,760,08 30,0
35,5 - 7,860,12 30,0 35,0 - > 0,05 Peptostreptococcus 8,110,47
70,0 71,3 8,720,34 30,0 37,6 > 0,05 8,330,22 50,0 58,3 > 0,05
> 0,05 Clostridium 3,40 10,0 9,1 6,970,22 40,0 42,5 - 0 - -
-
2. E. coli 5,170,17 100,0 63,7 8,780,18 100,0 133,8 < 0,01
6,840,17 100,0 101,5 > 0,05 < 0,01 E. coli Hly+ 0 - -
8,390,24 40,0 51,2 - 0 - - - - Proteus 3,120,14 50,0 20,8 4,200,20
100,0 64,0 < 0,01 3,500,07 60,0 31,2 < 0,05 < 0,01
Klebsiella 0 - - 6,290,24 50,0 47,9 - 0 - - - - Pantotea 0 - -
6,320,26 40,0 38,5 - 5,610,09 40,0 33,3 - < 0,05 Edwardsiella 0
- - 6,850,07 30,0 31,3 - 0 - - - - Enterococcus 8,710,22 90,0 104,5
8,160,39 80,0 99,5 > 0,05 8,160,17 70,0 84,7 > 0,05 > 0,05
Staphylococcus 3,400,18 30,0 14,0 4,480,20 50,0 33,8 < 0,01
4,690,07 20,0 13,9 < 0,05 < 0,01 Bacillus 9,360,35 80,0 124,8
8,130,50 70,0 86,8 < 0,05 8,910,21 60,0 79,3 < 0,01 < 0,05
C. albicans 0 - 4,070,23 40,0 24,8 - 0 - - -
: , , - , - (), 1 - 20-
2. 15 20-
20 /2 (n=10)
(n=10) 15
(n=10) (lg
/) Mm
(lg
/) Mm
(lg
/) Mm
1
1. Bifidobacterium 6,650,27 90,0 103,4 4,750,45 57,1 56,5 <
0,05 6,600,11 100,0 188,5 > 0,05 < 0,05 Lactobacillus
6,830,14 100,0 118,0 5,420,07 100,0 112,9 < 0,01 5,380,18 80,0
77,3 < 0,01 > 0,05 Eubacterium 5,340,27 20,0 18,4 0 100,0 - -
0 - - - - Bacteroides 6,500,18 100,0 113,8 5,640,17 100,0 117,5
< 0,05 6,520,09 100,0 117,1 > 0,05 > 0,05 Peptococcus
3,220,19 20,0 11,1 4,600,03 42,9 41,1 < 0,05 5,690,08 20,0 20,4
< 0,05 < 0,05 Clostridium 0 - - 4,820,10 57,1 57,3 - 0 - - -
-
2. E. coli 5,770,19 100,0 99,7 5,020,41 100,0 104,6 > 0,05
6,150,08 100,0 110,4 > 0,05 < 0,05 Proteus 0 - - 3,660,17
42,9 32,7 - 3,670,05 30,0 14,8 - > 0,05 Pantotea 0 - - 0 - - -
4,720,07 30,0 25,9 - - Edwardsiella 0 - - 4,760,09 42,9 42,5 - 0 -
- - - Enterococcus 6,170,22 70,0 74,6 4,580,44 42,9 40,9 < 0,05
5,810,11 60,0 62,6 Staphylococcus 0 - - 4,700,17 42,9 42,0 - 0 - -
- - Klebsiella 0 - - 4,890,15 28,6 29,1 - 0 - - - -
: , , - , - (), 1 - 20-
-
25
, 2012, . 19, 4
. 15 -
, (60-70%) . - . 15 - , , - 3 . - . , , (E. coli Hly+, ) .
1.
20 - - , - , - Bifidobacterium, Lactobacillus,
Enterococcus,Bacteroides, Peptostreptococcus .; -, , , , - .
2. 15 - - , - -
3. 15 20-
20 /2
(n=10) (n=10) 15
(n=10) (lg
/) m
(lg /) m
(lg
/) m
1
1. Bifidobacterium 6,710,23 60,0 74,6 4,500,22 60,0 50,2 <
0,01 6,000,12 100,0 108,3 < 0,05 < 0,05 Lactobacillus
5,780,35 80,0 85,6 4,420,20 70,0 57,5 < 0,05 5,330,12 60,0 57,7
> 0,05 < 0,05 Eubacterium 5,970,19 30,0 33,2 0 - - - 5,990,09
30,0 32,4 > 0,05 - Bacteroides 6,260,10 100,0 115,9 6,070,15
100,0 122,8 > 0,05 6,230,10 100,0 112,5 > 0,05 > 0,05
Peptococcus 0 - - 6,030,06 50,0 56,0 - 5,560,10 30,0 30,1 - <
0,05 Peptostreptococcus 5,810,15 50,0 53,8 5,350,13 30,0 29,8 >
0,05 6,270,12 40,0 45,3 > 0,05 < 0,05 Clostridium 0 - -
6,050,16 40,0 44,9 - 0 - - -
2. E. coli 3,090,14 100,0 57,2 6,290,14 100,0 116,9 4,950,09
100,0 89,4 < 0,05 < 0,01 E. coli Hly+ 0 - - 5,510,19 30,0
30,7 - 0 - - - - Proteus 3,570,33 70,0 46,3 4,600,40 100,0 85,5
< 0,05 3,500,07 40,0 25,3 > 0,05 < 0,05 Klebsiella 0 - -
5,260,26 30,0 29,3 - 0 - - - - Pantotea 5,78 10,0 10,7 4,520,38
30,0 25,2 - 4,890,09 30,0 26,5 - > 0,05 Edwardsiella 5,78 10,0
10,7 5,890,06 30,0 32,8 - 0 - - - - Enterococcus 6,010,16 70,0 84,3
5,030,05 40,0 37,4 < 0,01 6,340,14 70,0 87,7 > 0,05 < 0,05
Staphylococcus 3,78 70,0 7,0 4,790,11 30,0 26,7 - 3,890,06 20,0
14,0 - < 0,05 Bacillus 6,290,18 80,0 93,2 6,330,21 50,0 58,8
> 0,05 6,980,17 60,0 75,6 > 0,05 < 0,05 : , , - , - (), 1
- 20-
4. 15
20- 20 /2
(n=10) (n=10) 15
(n=10) (lg
/) m
(lg /) m
(lg
/) m
1
1. Bifidobacterium 6,390,17 100,0 167,2 4,750,25 40,0 61,7 <
0,01 5,900,11 100,0 104,1 < 0,05 < 0,01 Lactobacillus
5,680,21 80,0 111,9 4,600,24 50,0 74,7 < 0,05 5,000,06 70,0 61,7
> 0,05 < 0,01 Eubacterium 4,320,29 40,0 46,5 0 - - - 4,890,08
30,0 95,9 > 0,05 - Bacteroides 4,890,24 100,0 120,4 3,390,19
100,0 110,1 < 0,05 6,660,12 100,0 117,5 < 0,05 < 0,01
Peptococcus 0 - - 2,530,11 40,0 33,9 - 0 - - - - Peptostreptococcus
4,840,37 40,0 47,7 0 - - - 5,680,07 30,0 30,1 < 0,05 -
Clostridium 0 - - 2,170,09 60,0 42,3 - 0 - - -
2. E. coli 3,650,28 100,0 89,9 2,680,17 100,0 87,0 < 0,05
4,640,08 100,0 8,16 < 0,05 < 0,01 E. coli Hly+ 0 - - 2,010,05
40,0 26,1 - 0 - - - - Proteus 0 - - 3,500,28 40,0 45,5 - 0 - - - -
Enterococcus 5,650,44 80,0 111,3 0 - - - 6,890,21 60,0 72,9 <
0,05 - Staphylococcus 0 - - 2,090,06 50,0 33,9 - 0 0 - - -
: , , - , - (), 1 - 20-
-
, 2012, . 19, 4
26
, , , - Candida. -, Bifidobacterium, Bacteroides, Enterococcus,
Peptostrep-tococcus ; - , - .
3. - , - 20- - , - - , , ,, , - .
-
.
1. ..
/.., .., ....: ,2009.-312.
2. .. - 20- 20 /2./ ..// . 2011.- ..,3.-.71-75.
3. .. 20- - 20 /./..// - . 2011.-4.-.87-91.
4. .. 20- 20 /2 15 ./.., ..// . 2011.-3.-.44-47.
5. .. - 20- 20/2 ./ .., ..// - . 2011.-4.-.18-21.
6. .. Candida ./ ..-, ..// . 2011.- ..,4.-.144.
7. .. Candida 20- - 20 /2. /..// . 2011.-..,4.-.145.
8. .. , - Candida. /.. // - . 2012.-1.-.22-24.
9. .. 20- -
20 /2./..// . 2011.- .6.,4.-.36-41.
10. Bergeys Manual of Systematic
Bacteriology./D.R.Boone.,R.W.Gastenhdz., M.George [et al] New York:
Springer Verlag; 2001. .56-59.
11. Dobler G.Recent taxonomic changes and update of
nomencla-ture for bacteria identified in clinical material./G.
Dobler,I.Braveny//Eur j Clin Microbiol infect
Dis.-2003.Vol.22.-P.643-646.
.., ..
- , 20-
. 15 - - , , , , Candida. -, Bifidobacterium, Bacteroides,
Enterococcus, Peptostreptococcus ; - -, -. - , 20- , , - - , , , -
.
: , - , , .
Gamorak G.P., Kutsyk R.V.Bifidumbacterin Efficiency in the
Recovery of Qualitative and
Quantitative Composition of Cavity and Mucous Microflora of
theColon and Distal Part of the Small Intestine in Animals after
20-Days Exposion to Skin Application of Itaconic Acid
Summary. Oral use within 15 days after application of
Bifidum-bacterinum itaconic acid for decontamination of pathogenic
and con-ditionally pathogenic bacteria, as well as for correction
of qualitativeand quantitative composition microflora oral colon
and distal smallintestine leads to the elimination of these
habitats pathogenic and op-portunistic Enterobacteria, Peptococci,
Clostridia, Staphylococci andfungi of the genus Candida. This
growing population level indigenousobligate anaerobic, facultative
anaerobic and aerobic bacteria genusBifidobacterium, Bacteroides,
Enterococcus, Peptostreptococcus andother representatives of the
main microflora this habitat, reduced thenumber of conditionally
pathogenic representatives microbiocenosisrelating to additional
and residual microflora. Bifidumbacterin improvescolonisation
resistance of the mucosa of colon and distal small intes-tine of
experimental animals, which previously held 20-day applica-tion
itaconic acid by bifidobacteria population habitat of animals
andincreasing population levels of autochthonous obligate
endogenousmicroflora and significant decrease in opportunistic
Enterobacteria,Peptococi, Staphylococci and other, leading to
improved colonisationresistance of the mucosa of colon and small
intestine.
Key words: normal microflora, colon, small intestine,
itaconicacid, Bifidumbacterinum.
27.08.2012 .
-
27
, 2012, . 19, 4
616-08+616.831-005.1+615.225
.., .. ( . . - . ..) -
. - . - NIH-SS, , MMSE. , , NIHSS 25,6% MMSE 15,0% , (p
-
, 2012, . 19, 4
28
(95,0%), -(78,3%).
1 NIHSS (.1) 7,270,45 , 2 7,850,53 3 7,610,44 . - 1 NIHSS
6,440,44 (p>0,05). 2 - 18,47% 6,430,48 (p
-
29
, 2012, . 19, 4
. 2 3 . - 3 90- , . 1 , 2 , 3 .
,
- .
, - , - , - .
- - .
- - - .
1. .. : -
/ .. // 2006. 14, 1. . 15-18.
2. .. : , , -, , / .. -, .. : , 2003. 44.
3. .. / .. , .. // . 2012. 3 (49). . 181184.
4. .. - . /.. , .. // . 2011. 17, 1. . 1925.
5. .. - / .. , .. , .. // Consilium Medicum. 2010. .12, 2.
.512.
6. .. ( ) / .. , .. -
, .. , 2008. 35.7. -
487 17.08.2007.
8. - / ..,.. , .. , .. // . 2010. 3 (14). . 34.
9. Alvarez-Sabin J. Citicoline in vascular cognitive
impairmentand vascular dementia after stroke / J. Alvarez-Sabin, G.
C. Roman //Stroke. 2011. Vol. 42. P. 4043.
10. Fisher M. New approaches to neuroprotective drug
develop-ment /M. Fisher// Stroke. -2011. Vol. 42. P. 2427.
.., .. -
. -
- . - NIHSS, , MMSE. , - , - NIHSS 25,6% - MMSE 15,0% , - (p
-
, 2012, . 19, 4
30
[5]. - - , [6]. , - - [7; 8]. , (- ) - .
- - - .
-
, 12. - (0,25%) 37 (15 ). - (10%, 2 ) - . (10%) 5% 0
2 37.
(0,25%) (0,06%) 1:5.
18 - (. 1). - 3 , .
1, . (2 2 ) . 2 -
( Panmed). - , . .. . . (2007) [9].
. 2. -
, . - - .
- - 400-600 (.1).
, - (. 2).
, , , , .
,
1. ,
Cavex, MajorDental, Voco, MajorProdotti, Zhermack, Dentsplay,
SpofaDental, Shanghai, -04 Stoma, Lascod, - Zhermack, Zhermack,
Dorident, - Dentsplay, SpofaDental, Septodont, Zhermack,
Zhermack,
2.
1 2 3
- - ,
- - ,
- - ,
Mm,
- 527 549 584 55328 410 440 425 42515 555 580 495 54342 500 480
507 49613 520 525 590 54535 651 660 648 6536 799 784 792 7927 560
584 555 56614 510 520 515 5155 562 571 583 57210 412 400 406 4066
615 640 628 62712 610 600 580 59715
-04 410 414 505 44348 314 345 340 33316 340 325 310 32515 412
440 445 43217 - 555 560 580 56512
0
100
200
300
400
500
600
700
800
900
-
-04
-
-
1.
0
100
200
300
400
500
600
700
-
. 2. Zhermack,
-
31
, 2012, . 19, 4
. , - -, - - .
, - .
, Jeltrate - (7927 ) - (32515 ). - .
, - Jeltrate, , , . Samueletal. (1995), - -.
, , .
, , - , , .
,
:1. -
- .
2. .
3. , .
- - -.
1. . . -
/ . . . -. . . . . 14.01.22 .- . 2010. - 24 .
2. Relating themarginal fitofthecasting stotheac curacyof
theim
pressions made from laminated hydrocolloid impression technique:
acomparativestudy / M.R.Sinha, B.Thakur, A.Gaikwad, [et al.] // J
Con-tempDentPract. -2012 Mar- 1;13(2). - P. 167-172.
3. : / . ., . . , . . ; .. . . . -.: . - 2010. - . 141-145.
4. / . ., . . , . . , . . . -. , 2005. - 52 .
5. / . .. . . - .: . . , 2005. - 506 .
6. Muzaffar D Dimensional changes in alginate impression
duringimmersionin a disinfectant solution. / D. Muzaffar, S. H.
Ahsan, A.Afaq // J. Pak. Med. Assoc. - 2011 Aug. - N. 61(8). - P.
756-759.
7. Theeffectof a rangeof disinfectants on the dimensiona
laccuracyof some impression materials. / D.C.Jagger, Al. O.Jabra,
A.Harrison,[et al.] // Eur. J.Prosthodont. Restor. Dent. -2004.
-Dec. - N. 12(4). - P.154-160.
8. Beganovi M. Theeffecto flevel sofalkalisaltsin Alginate
-LF-250 onphysico-mechanical properties of material sused in
makingimpressions based on irreversible colloids / M.Beganovi//
MedArh. -1992. - N. 46(1-2). - P. 11-12.
9. . . / . . , . . // .- 2007. - . 49. 3. - . 204-209.
.. -
. , -
- -, .
. , Jeltrate, .
: , -, .
Grizodub D.V.Investigation of Cytotoxicity of Dental Alginate
MaterialsSummary. An article devoted to the urgent problem of
modern
prosthetic dentistry - prevention of intolerance to dental
materials alginates. Author raising questions about the
cytotoxicity of this classof impression materials.
In summing up the results of the study author indicated
reactioncytotoxicity alginate materials from different
manufacturers. It wasdetermined that the best alginate Jeltrate,
the highest degree of cyto-toxicity expressed Tropikalgine and
Ypeen.
Key words: alginate materials, cytotoxicity, dental
materials.
08.10.2012 .
-
, 2012, . 19, 4
32
616.31:616.127-005.8-085.212.3:547.587.11
., ..- , (. . - . ..) . ..
. , , - (), - . - ()., 50% , , , 70% - . , , , 1 - - , - . - -
CD- , , . - , -.
, , .
. - , - - [7-11]. - -, - [1,4,9].
, (-,, ) [3]., , - [1,5]. , , .
, , - , - . - () , [2,5].
, - ( - - ) [6], - .
: - , .
90 35 65 , , .. .. .
1 5 (, 75 ), - . , -: 1 - - 47 , 1 4, 2 - 43 , , 1 .
, , - , , -- .
( - , - , - ), (--) ( - () Parma %, - () , Muchle-mann). - ..
(1994), Miller.
CD4+, CD8+, CD4 /CD8, CD16+, CD54+ CD95+ - .
Statistica 5 for Windows. - ( ). Mm (M- , m- ). - t . - (0,95),
- , p
-
33
, 2012, . 19, 4
, , 2,6 .
23 (48,97,3%) - , 1,4 , 5,7 , , 1 .
(, ) 924,1% 517,3% - , -, . - - .
(CD- ) , , CD4+- ( - ) CD8+- (- -). CD4/CD8 ( ) - CD8-.
, (CD16+), ( 22,090,60 37,140,61 ). -, (NK- ) - CD16 . , , .
, -1 , - (49,090,74). , - (36,640,82) (p
-
, 2012, . 19, 4
34
aspirin have dental complaints, and over 70% are due to
pathologicalchanges of hard tissue of teeth and periodontal
tissues. Shown thatpatients taking aspirin at least 1 year, have
more pronounced changesof hard tissue of teeth and periodontal
tissue to spread and severity ofclinical symptoms, which is
confirmed by index numbers. Conductingtyping leukocytes in scrapes
with the gum on the expression on thesurface of clusters of
differentiation, shows an increase in the contentof all tested CD -
markers in patients who have recently taken aspirin,
not only in comparison with the norm, and when compared to
theother subgroups. The necessity of cooperation of doctors -
internistsand dentists for early diagnosis of violations, as well
as developing analgorithm for their treatment and prevention.
Key words: coronary heart disease, acetylsalicylic acid,
periodon-tal.
29.10.2012 .
616-08+616.12-009.72+616.12-008.331.1+616.12.008.931.1+615.27
.. L- () -
. - - - L- () . 55 -. , -, .
: , -, , .
. , - , . -- . () - () , , , - , . - [1, 2].
- . , - , - , , , ; - , , . - (NO), -- . NO - NOS . NO - - . , ,
, - . , NO - , -. , , - [5, 8].
- , , , - . - L-() ().
, ,, , , - , , , - VCAM-2 MCP-1, - , --1. - - . -, L- -, -, [1,
4,7, 8].
. - - - - , - . , - , , - , [3].
- - .
: - - L- () ().
55 -
, 59,4 (1,7) . 36 (65,5 %),
-
35
, 2012, . 19, 4
- 19 (34,5%). 20 - . - : () - 27 , (- , -), ( ), (), () - (++),
28 , , , - (4,2 L-) 100,0 , 10 15 (3 ) 2 / 1- , - [ 10 2,0 5% , ,
200,0 0,9% , 30-90 1 0,1 3 ]. - 1 . - (total NO) D.Celermajer,
K.E.Sorensen (1992).
, - . - - (- -) (- ) Logia 500(Kranzbihler, ) 7,5 -, Celermajer,
K.E.Sorensen (1992).
Statistica 8,0. t- - .
-
, 2012, . 19, 4
36
1.
- ( , , ).
2. - : , , - .
- , - .
1. .. L-
/ .. // . . . 2009. 74(XI/X). . 43 48.
2. .. - / .. , .. //Medicine Internal. 2008. 2(8). . 36 41.
3. .. - , / .. , .. // . 2010. 2(138). .58 62.
4. L- / A. Orea-Tejeda, J.J.Orozco-Gutierrez, L.
Castillo-Martines [and others] // Therapia. - . 2012. 5(69). . 44
48.
5. .. / .. // . 2008. 3. . 21 26.
6. L- - - : - / Y. Bai, L. Sun, T. Yang[and others] // Therapia.
. 2011.10(62). . 45 51.
7. .. -
/ .. // .2009. 5 (73). . 40 43.
8. .. - - / .. , .. ,.. // Therapia. . 2012.3(67). . 71 74.
.. -
L- () -
. L- () - . 55 ., , - .
: , , , .
Zozuliak N.V.Protection of Endothelium in Patients with Stable
Angina FC
III with Concomitant Hypertension and its Correction by Using
ofNitric Oxide Donator L-Arginine and Metabolic Drug Mexicor
Summary. The purpose of this study was to evaluate the
effective-ness of treatment of patients with stable angina pectoris
III FC withHypertension in the background of the application of
basic therapyand its combination with nitric oxide donor L-arginine
(Tivortin) andmetabolic drug Mexicor. It was examined 55 patients
with Stable An-gina pectoris III FC with Hypertension. It was
investigated that in thepatients the drugs Tivortin and Mexicor
reduce the signs of endothe-lial dysfunction and enhances
production of endogenous vasodilator -nitric oxide.
Keywords: Stable Angina, Hypertension, nitric oxide,
endothe-lial dysfunction.
26.06.2012 .
: 616.097+612.118+612.68
.. 0 (. . . ..) -
. 0 (Rh) -. 0 - () (39,09 %). 0 - : -()>()> 0()>(V)
0()>()>()>(V). 86,97% (Rh+), 85,95%. , - .
: , , .
. ,
, -, . - -, - . , - , - - [1]. , - , -, . (. 1) [2].
. (+) ; (-) .
-
37
, 2012, . 19, 4
- ; - ; - ; - ; C - -- ; - - ; - - .
- , - . - , . - -- , - .
, 0, Rh, MN, Le, P [3-8]. , [3-6]. -
.
0 (Rh) - .
-
412 220 ( ). - 10 .
( ) - , 0 ++ 0, :
/0 - . 1 - . 1, - [9]. - 2 - (Odds Ratio (OR)) [10, 11].
0 . - . - - 0 . (0) 36,66 % 23,81 % (.2). () (39,09 % 28,57 % ).
, () 1,72 , . - IV () . - (14,29 % -4,84 % ).
.
(. 3.1, 3.2).
, (0) . () IV () .
0 -- : ()>()>0()>(V), 0()>()>()>(V).
- -
1. ,
-
-
- (- , )
,
-
( )
+
-455 2 +
-IV -
( , )
? +
, , , +
Y2D6,CYP2C19 219
450 ?
HL I II
+
P53 , - V,VII, PAI-1
,
, +
FR
, +
-
, ? ?
+
RP , ? -
(- )
/- ? -
G (-)
-
, , , -
G2b -
? -
? +
TH-INS-Fokl
-
SOD2 ,
? +
WRN () +
0
0
2. 0
0
-
-
2 OR,
0 () 52 (23,81%) 152 (36,66%) 10,55 1,87 (1,29-2,69) =0,001
() 63 (28,57%) 162 (39,09%) 6,38 1,60 (1,12-2,26) =0,012
() 74 (33,33%) 78 (19,38%) 16,18 0,46 (0,32-0,67) =0,000
(V) 31 (14,29%) 20 (4,84%) 3,84 0,31 (0,18-0,56) =0,000
-
, 2012, . 19, 4
38
Rh . 86,97% (Rh+), 85,95%. , - (19 %), (17%), (16%) (16%), ,
(1,1%) (0,35%). - Rh , , 24,17% Rh 9,52% - (. 4).
Rh
. - , -. , - , .
0 (. 5).
4, 0 (), (V) (). (), (V) (), 1.
- 0, . 0 Rh (. 6).
, 0 0 - , (), () (V). 0 -: 0()>()>()>(V). (), (), (V) -
. - . 0 - : ()> 0()>()>(V). - .
,
() (39,09 %). 0
:- ()>()> 0()>(V) 0()>()>()>(V).
, ( 90,48 % 75,83 %)
, 0 : 0()>()>()>(V), - ()>0()>()>(V).
- .
1. .., .. ,
/ .. , .. // . . 2007. .6, 4 (58). . 17-29.
2. .. - . / .. .: , 2003. 468.
3. .. - . / .. // . 1990. - 2. . 3536.
4. .. : .3- . / .. .., , .. ., 1976: 115 .
5. .. , MN. . / .. // . 1979. - 3. . 232233.
6. .. , MN, P, Ie, Hp.
3.1. -
0
2 OR,
0 () 17 (7,74%) 44 (10,68%) 1,11 1,43 (0,79-2,51) =0,291
() 32 (14,54%) 51 (12,38%) 0,42 0,83 (0.51-1,33) =0,519
() 17 (7,74%) 45 (10,92%) 1,31 1,46 (0,81-2,56) =0,252
(V) 16 (7,27%) 16 (3,88%) 2,76 0,52 (0,26-1,04) =0,097
3.2. -
0
2 OR,
0 () 37 (16,81%) 100 (24,27%) 4,26 1,59 (1,04-2,39) =0,039
() 32 (14,54%) 97 (23,54%) 6,60 1,84 (1,16-2,77) =0,010
() 53 (24,09%) 41 (9,95%) 21,54 0,35 (0,22-0,55) =0,000
(V) 16 (7,27%) 8 (1,94%) 9,75 0,25 (0,11-0,61) =0,002
4. Rh -
Rh+ 75,83 % 90,48 % Rh- 24,17 % 9,52 %
5. 0
0
0: 1,109 0: 2,627
0: 4,305 :0 0,901 : 0,380
: 0,232 : 1,638
6.
0, Rh
0 0 Rh+ : Rh+ 1,142578 0 Rh+ : Rh+ 2,68125
0 Rh+ : Rh+ 3,988636 Rh+: Rh+ 2,346667
Rh+: Rh+ 3,490909 Rh+: Rh+ 1,487603
0 Rh- : Rh- 0,857143 0 Rh- : Rh- 1,125
0 Rh- : Rh- 6 Rh- : Rh- 1,3125
Rh- : Rh- 7 Rh- : Rh- 5,333333
-
39
, 2012, . 19, 4
. /.. // . , . - 1982. - 10. . 6668.
7. The role of genetis polymorhisms in environmental health /
S.N. Kelada, D.Eaton, S.S. Wang et all // Environmental Health
Per-spectives. 2003. Vol. 111.- P.1055-1064.
8. .. 0 / .. // - . 2011. . 18, 3. . 77- 80.
9. .. / .. . .: -. 1997. 288 .
10. .. - . . - [] / .. , .., .. // . .. 2003. . 32, 4.
.138-144.
11. .. - . . : , , []/ .. , .. , .. // . .. 2005. 2 (46). .
113-119.
..
0 .
0 (Rh) . 0 ,
(II) (39,09%). 0 - : - (II)> (III)> 0 (I)> (IV) 0
(I)> (II)> (III)> (IV). 86,97% - (Rh +), 85,95%. , .
: , , .
Kozoviy R.V.Calculation of Odds Ratio of Longevity in
Precarpathian Re-
gion by System of Antigens of Blood Group AB0 and RhSummary. The
features of distribution of blood group antigens on
systems A0 and Rhesus (Rh) in the population of the
Precrpathian.Analysis of association life from the antigens of
blood groups and Rhsystems A0 found among of the Precrpathian
highest percentage ofowners of phenotype A (II) (39.09%). Over the
frequency of antigenphenotypes of A0 among centenarians set the
division as follows:male centenarians A (II)> (III)> 0
(I)> A (IV) and women 0 (I)> A(II)> (III)> A (IV). In
86.97% of long manifest sign of Rh (Rh +),in the control group, the
same sign manifested in 85.95%. The resultsallow for a
comprehensive approach to creating prohnotychnyh fore-casting
models for longevity in humans.
Keywords: longevity, blood types, population.
29.10.20102 .
616.147.3-002.17-08.039.57-073,48
..1, ..2, ..1
, (. . - . ..)1 - (. . - . ..)2 ..
. 58 , 4-6 -, 2 . , 28 (35 ), . 30 (37 ) - - . 24 (85,71%) - . -
27 (90,00%) . - , . - 4-6, - -, , , .
: , - , , -.
. - 15% , [11].
() [4, 15]. - ( 2-) - [1, 3]. - ( 4-6) (6).
, , - . , - - , - - , - - , [8, 12, 15].
[5, 7, 9, 14]. - -. , . . - - (1, 2,10, 15) (2, 3, 4) (6,
13).
-
, 2012, . 19, 4
40
, .
: - - .
58 -
. 2 . , - - . 28 4-6 ( 35 ). () 4 17, 5 6, 6 5. 30 (37 ) 4 15, 5
9, 6 6. 3,5 8 . 4 . - , (, - ).
: - ; - ; - - ; -, .
- - : ( ), 3- ; 2,5 5,0 ; ( 70%, - ); ; ; ; (, ) ; 21-22G. , - .
Esote My lab 30 () 7,5-12 . - .
-. . - . , . . . , . , . .
. -, - , , . .
-
. - , . 2 3 5% .
- , - , . , , , . (4-6 /) - , , -, - .
- . - . - . , - 0,5% 0,25% . 18G, , , . - - 940 . - 14-18 - (50
50 ). - 5-7. 0,5 2 , 70-80 1 .
- , -. -. 5-7 , -. - -. - .
7-10
. . 3-6 7 -, . - . 6-12-18 4- , 3 , - . 24 (85,71%) - 28 , ,
.
6-12 5 . 3- , - - 2-, - - . 27 (90,00%) -.
, - , -
-
41
, 2012, . 19, 4
. , . 2-3. 6-12 : , , , , , .
- - , . - , 4-6, , - - , - .
-
, , - - - .
- - , , - .
- ( 1-3- ) - .
1. .. -
, // I - . - . - 2012. - . 6. - 2. - . 101-102.
2. .., .., .. - // I - . - . - 2012. - . 6. - 2. - . 89.
3. .., .. - // I - . - . - 2012. - . 6. - 2. - . 80.
4. // . .. - .: . - 2009. - 187 .
5. - - / .., X. , .., . // - . - 1998. - . 4. - 1. - .
20-30.
6. / ..,.., .., .. // : . -2007. - 79 .
7. B.C., .. // - . - 1997. - 3.- . 24-26.
8. // .., .. - :. - 1984. - 180 .
9. Subfascial endoscopic perforator vein surgery combined
withsaphenous vein ablation: results and critical analysis /
Bianchi C., Bal-lard J.L., Abou-Zamzam A.M., Teruya .. // J. Vase.
Surg. - 2003. -Vol. 38, 1. - P. 67-71.
10. Guex J.J. Ultrasaund guided sclerotherapy (USGS) for
perfo-rating veins (PV) // Hawaii Med J.- 2000.- Vol. 59. - p.
261-262.
11. Jantet G. Chronic venous insufficiency: world vide results
ofthe RELIEF study // Angiology.- 2005. 53. - P. 245-256.
12. Kalra M., Gloviczki P. Surgical treatment of venous
ulcers:role of subfascial endoscopic perforator vein ligation //
Surg Clin NorthAm - 2003. - 83. - . 671-705.
13. Schadeck M. Die Duplex-controlierte
sklerosierungsbehand-lung // Phlebologie.- 2001.- Vol. 30. - .
94-100.
14. Tawes R., Wetter L., Hermann G., Fogarty T. Endoscopic
tech-nique for subfascial perforating vein interruption // J.
Endovasc. Surg.- 1996. - 3 - . 414-420.
15. Thibault P.K., Lewis W.A. Recurrent varicose veins: II:
injec-tion of incompetent perforating veins using ultrasound
guidance //Dermatol Surg. Oncol. - 1992.-Vol. 18. - p. 895-900.
.., .., ..
. - 58 -, - 4-6 , 2 . , 28 (35 - ), . - 30 (37 - ) - . 24
(85,71%) - . - 27 (90,00%) . - , -. - 4-6, - , - , .
: , - , , .
rysa V.M., Hodos V.., Krysa B.V.Ambulatory Foam
Scleroobliteration and Endovasal Laser
Coagulation of Helpless Perforator Veins Under Ultrasonic
Con-trol
Summary. The results of treatment are analysed in
ambulatoryterms 58 patients with varicose illness of lower limbs
and chronic venousinsufficiency of C4-C6 of classes, divided into 2
groups. In the firstgroup in which included 28 patients (35
helpless perforator veins), attreatment applied foam
scleroobliteration of perforator veins. In thesecond group 30
patients (37 helpless perforator veins) of endovasallaser
coagulation. In 24 (85,71%) patients after foam sclerooblitera-tion
it was succeeded to attain the complete occlusion of helpless
per-forator veins. After endovasal of laser coagulation complete
occlusionof helpless rerforator veins attained patients in 27
(90,00%). Findingdid not educe substantial differences at the use
of both methods in anamount complications and in end-point of
treatment. For patients withchronic venous insufficiency of
functional class C4-C6, in connectionwith the risk of post surgical
complications in the area of trophic disor-ders, both methods of
removal of horizontal refluxus effective, each ofwhich advantage
gives oneself up depending on equipped of clinicand experience of
specialist.
Keywords: varicose illness, helpless perforat veins,
sclerooblit-eration, endovasal laser coagulation.
08.10.2012 .
-
, 2012, . 19, 4
42
616-08+615.22+616.12-008.331.1+616.12-009.72
.., .., .., .., .., .., .. , (. . - . ..)-
. 90 , - - ( ), (, ). - - , . - . - .
: , -, , , .
. () () 4 , - [3]. -, . - , , - [1]. - , , [2, 4]. , - , -. - -
[5, 6, 8, 9].
, - , . , [7, 10]. -: , , , , . - -, .
. - - ( - ) ) - - II .
90
, , - ( , , , , , - , ), ( 200) . 2 , , ( 60,2 , - 2,60,15 ,
- 75 , 20 ). 7-14 . 44 () 1 3 . 1- 100 .46 , 1 (). , 0,5 , -
.
, -.
. (t).
7 2, 2 0,780,10 (
-
43
, 2012, . 19, 4
, - , 159,81,9 . 122,90,7 . . 162,01,9 . 121,00,8 . . (
-
, 2012, . 19, 4
44
613.955+616-08
.. (. . . ..) -
. , - , - , . - . - - (
-
45
, 2012, . 19, 4
- - (
N
-
, 2012, . 19, 4
46
(N
-
47
, 2012, . 19, 4
8. . . / . . , . . // .. .- 2010.- 2.- . 66-69.
9. . . - / . . / .- 2006.- 5.-. 6-7.
10. . . - / . . // . -. .- 2008.- 4(15).- . 45-49.
11. . . / . . , . . , . . // ,2010.- 226 .
12. Bush A. How Phenotip Differences between Pediatric and
AdultAsthma / A. Bush, A. Menzies // Amer.Thorac. Soc.- 2009.- Vol.
6.- P.712-719.
13. Global strategy for asthma management and prevention /
Na-tional Institute of health. National Heart, Lung and Blood
Institute. Update, 2009.- 112 p.
.. -
.. ,
, , - . .
(
-
, 2012, . 19, 4
48
, , . - , - . , - . -- - [5, 9]. .
80
: 21 54 . 55 , - , - () 124 1 2 14 . - 25 , . - 25 . 593
02.12.2004 , . , .
- , - 115 , (,).
. Statistica 6,0 for Windows.
, , - , . , .
(. 1) (. 2) -.
. 1 , -
- 9,520,48
2
2/ (
-
49
, 2012, . 19, 4
- .
1. -
.
2. - -, - .
-
.
1. .. -
/.. , .. // .2007.-8..3-15.
2. .. : / .. , .. , .. .// - .-2011.-3.- .34-44.
3. .. / .., .., - . . // .-2011.-2.- .5-17.
4. .. - / .. , . - // . . 2010.- 3(27). .68-72.
5. .. -/.. // . .-2005.-3.-.42-47.
6. 593 02.12.2004 .
7. .. / .. // -.-2005.-5.- .62-67.
8. .. - - / .. , .. , .. /
/ . - 2011. - .15, 2. - .78-80.9. ..
// , .-2010.-.39.-.100-103.
10. Jacquillet G. Zinc protects renal function during cadmium
in-toxication in the rat / G. Jacquillet, O. Barbier, M. Cougnon
//Am. J.Physiol. Renal.-2008.-V.290, 1.-P.127-137.
..
. 80
I II : . - 55 , - , 124 1 2 14 . 25 - , . - , , - . - - () (), -
. - .
: , , -, .
Lisnyanska I.S.Modern Aspects of Treatment of Patients with
Chronic Pyelo-
nephritisSummary. The study involved 80 patients with chronic
kidney
disease stage I and II: pyelonephritis in the acute stage.
Investigatedgroup included 55 patients who received approbated
therapy whichincluded basic drug therapy with the addition of zinc
sulfate at a doseof 124 mg 1 tablet 2 times a day for 14 days. The
control group includ-ed 25 patients with CPN who received basic
therapy. All patients stud-ied zinc content in blood, levels of
catalase, superoxidedismutase inserum by standard techniques. Is
proved zinc deficiency and disordersof lipid peroxidation (LPO) and
antioxidant system (AOS), which wasreflected by decreased activity
of AOS. These changes were correctedby adding to the basic drug
therapy of zinc sulfate.
Key words: chronic pyelonephritis, zinc, catalase,
superoxidedi-smutase.
29.10.2012 .
616-071+616-092+616.314.17-008.1+616-08+615.33+616.33-002+616.24-002+618.12-002
. ., . . (. . . ..) -
. 48 , - ( 64,6% 36,4% -). - , ( - C, - -).
-
, - - , , -.
: , , .
. - , , - , , -
-
, 2012, . 19, 4
50
, [2, 3, 4]. (), , - , - [5, 6, 10, 11, 12]. - , - [7, 8]. - , .
, - - [7, 8, 9].
-, .
- --
48 - ( ). (41,92 1,96) , 24 24 . , , 64,6% , 36,4% .
- : 18 ; 10 ; ( -) 12 ; - 8 . , -, , , -, - .
, - . 3 : (n=16) - () - ; (n=16) - - ; (n=16) - - - .
: ( , - ) , Woodpecker (Woodpecker Inc.,); ; - . - - (
Phytop-harm Klenka S.A., ) 2 , ( Sanofi-Synthela-bo S.p.A., ) 1 2 .
- - 2 .
- , 14 1 - . , .
: - () (Green J. C., Vermillion J.K., 1964), () SBI (Muhlemann
H. R., Son S., 1971), () (Parma, 1960), - (CPITN), ..(1970) [1, 2,
3]. - .. - (1994) [1].
-
- , - (1,90,07) , (1,70,05) (1,90,03) , . , 4,5% (=0,16).
14 - (2,1 0,03) ,
-
51
, 2012, . 19, 4
, (65,50,4)%, (63,50,5)% (64,50,4)%. , - , -- - . - 3.
- (CPITN) - (3,510,04) . - (3,370,03) (3,450,04). - - . CPITN
(0,690,02) , (0,630,03) . CPITN (3,450,05) - , , , - , - . CPITN -,
(0,570,03) (
-
, 2012, . 19, 4
52
, / .. , .. -, .. // . 2004. 3. . 610.
6. .. - - / .. , . . , .. // . 2003. 1. . 812.
7. . . / .. , .. - // . 2008. 1-2. . 4853.
8. . . : - , , - / . . , . . -, . . // . 2005. 3. .3643.
9. . , , : - / .. , .. , .. ,.. . .: ,2004. 320 .
10. Azarpazhooh A. Systematic review of the association
betweenrespiratory diseases and oral health / . Azarpazhooh, J.
Leake // J.eriodont. 2006. Vol. 77(9). . 1465 1482.
11. Scannapieco F.A. Oral bacteria and respiratory infection:
ef-fects on respiratory pathogen adhesion and epithelial cell
proinflam-matory cytokine production / FA.Scannapieco, B. Wang ,
H.J. Shiau // Ann. eriodont.- 2001. - 6. . 7886.
12. Sumi Y. High correlation between the bacterial species in
den-ture plaque and pharyngeal microflora / Y. Sumi, H. Kagami,
Y.Ohtsuka, Y. Kakinoki, Y. Haruguchi, H. Miyamoto //
Gerodontology.- 2003. - 20. P. 8487.
.., .. -
-
. 48 -, - ( 64,6% 36,4% - ). , -
( - C, - - ).
- , , , - -.
: -, , .
atviykiv .I., Gerelyuk V.I.Clinical Status of the Periodontal
Tissues in Patients with
Chronic Generalized Periodontitis against the Backgraund of
Sys-temic Antibiotic Therapy of Concomitant Pathology
Summary. The study involved 48 patients with bacterial
pneumo-nia, which were diagnosed with chronic generalized
periodontitis(64,6% cases diagnosed with first degree and 36.4%
with the secondstage of development). Changes in periodontal
indices after systemicantibacterial treatment of other somatic
pathology tend to improve clin-ical picture in the oral cavity, but
the most pronounced positive effectobtained from our proposed
corrective treatment (receiving of the pro-biotic suspension
Enterozhermina in tandem with rinsing of the oralcavity by
antiseptic solution Stomatofit, usage of therapeutic andpreventive
dental herbal pastes and previously conducted professionaloral
hygiene).
Comprehensive measures have shown the importance of
timelyprovided professional oral hygiene, specifying the period of
its imple-mentation, which provides the basis to recommend and
widely use thistechnique in the periodontal practice, especially in
a hospital wherepatients remain under the supervision of general
practitioners and havelimited access to the dentists.
Keywords: chronic generalized periodontitis, somatic patholo-gy,
antibiotic therapy.
05.11.2012 .
616.714.1089.874+616.379008.64:616.36+616.61)+612.015.1]001.5
.. - (. . . .. ) . ..
. - . - -. - - , - - , - , - .
: - , ,, , , .
. , - , , - (), - , - - [7, 8].
, - - . , : , , , - . - . , - , , , , , - , , , [7].
, ,: ,
-
53
, 2012, . 19, 4
. , , : , [11]. - , (). - [6, 10, 11].
, () , . [1, 2, 9].
, , [1, 2, 11], .
: - , .
-,
: (), , -, , IV , .
- [4]. - (Sigma, ) 60 / [3]. 14-16 /. 3 24 ( ), 5 14 ( ) [4].
.
() (). () () (). -
. , - - . - t- .
, - [5].
-
. - , () () - . (. 1), 58,3, 53,8(
-
, 2012, . 19, 4
54
4,4 % 14 45,6,65,1 62,2 (
-
55
, 2012, . 19, 4
Meretskyy V.M.State of Lipoperoxidation and System of
Antioxidant Protection in
the Liver and Kidneys of Animals with Traumatic Brain Injuries
againstthe Background of Experimental Diabetes Mellitus
Summary. Traumatic brain injury is accompanied by increased
inten-sity of lipid peroxidation and early depletion of reserves of
antioxidantenzymes in liver and kidney tissue to a greater extent
during the acuteresponse to trauma. Experimental diabetes causes
significant activation ofLPO and inhibition of antioxidant defense
system in the liver and kidneys.
Diabetes in animals with brain injury causes greater
intensification of lipidperoxidation, strongly inhibits the
activity of enzymes- antioxidants andslow recovery dynamics of
these indicators compared with isolated braininjury, resulting in
the mutual burdening flow of these pathologies.
Key words: head trauma, diabetes, lipid peroxidation,
antioxidantprotection, liver, and kidneys.
17.09.2012 .
.., ., .. - . . ..
. , 106 1-2-, - - (, ) (, ) , , , . - , , - , , .
: , , , -, .
. , , - - [1, 3]. , , - - [2, 12]. - , () [11,20], - , ,
[7].
, - , - .
: - , .
106 - , 1-2 -
, 58,92,2 , 67% (18 ). 7- :
(100 /) - 26 8 ; (10 /) - 26 12 ; (20 /) 27 12 ; (10 /) 27 8
.
, , .
ABPM-04 (Meditech, ) -: 15 ( 7 22 ) 30 ( 22 7).
-- ( , ). , , -. Biosystems A25, ().
- -(Immunotech, ). - , :
= [ (/) (/)]/22,5
SPSS, 13. , , - - . t- ANOVA, . (Mm), , m - .
-
, 2012, . 19, 4
56
- . : - 19,5 21,9%, , . - , , - 11,8% (. 2), - , [17].
. 17,6 17,0% . (.2). , , 24 , 3,2/ ( - ). - , 4,90,3 4,20,2 /
(>0,05) .
, , , , - , . , ,
.
-, -, - . - . , - . - -
, . , , , - [16]. - .
: . , - . , ,
1
PPAR- , , , [10].
, - . -, Koh K. . 2004 - [13], Rayner B. i ., 2006 - ( 8,7%), -,
- - - [17].
- , NF - , [14]. -,
1 -
-1 -6 , NF, [18]. , , [5,6,9].
Madej A., 2009, 67 ,
1. ,
.. , ..
..
, ..
, ..
, ..
3 .
144,51,7 129,51,4*
87,31,6 76,61,4*
149,21,9 135,51,7*
90,51,4 80,71,4*
135,22,3
125,92,4*
78,52,3 70,21,3*
3 .
144,91,6 130,91,6*
86,71,4 77,41,1*
149,61,6 135,82,6*
90,21,4 81,51,6*
135,62,6
124,42,4*
79,41,9 71,11,3*
3 .
145,71,9 133,91,8*
87,41,4 79,61,3*
149,51,9 138,71,9*
90,81,3 82,11,4*
136,32,5
125,52,4*
80,41,8 73,31,7*
3 .
147,12,0 134,51,9*
88,21,9 78,51,5*
151,21,8 138,41,6*
91,41,7 82,21,7*
137,62,6
124,32,0*
79,92,1 71,31,8*
: *- : *p
-
57
, 2012, . 19, 4
-6, -1, -, P-1, -10 [15]. PERTINENT, EUROPA, , D- - [4].
. - Sanz-Rosa D, 2005 , , , , , [18]. , - , - . - Farah R. ,
2008 (60 - , 6 ), -, - , [8]. Yasunari K., 2004(104 , 8 ) , , , -
[19].
1. - -
( ) (- ) .
2. - , , , - , - .
3. , .
, - -, - , - .
1. ..
- - // -.-2012.-2.-.54-59.
2. Andrikou I. Similar levels of low-gradeiflammation and
arterial stiffnes in masked andwhite-coat hypertension: comparisons
with sus-tained hypertension and normotension/ Andrik-ou I.,
Tsioufis C., Dimitriadis K. [et al.]// BloodPress.
Monit.-2011.-Vol.16.-P.218-223.
3. Boos C.J. Is hypertension an inflammato-ry process?/ Boos
C.J., Lip G.N.// Cur. Pharm.Des.- 2006.-Vol.12.-P.1623-1635.
4. Ceconi C. ACE inhibition with perindopriland endothelial.
Results of a substudy of EU-ROPA study: PERTINENT/ Ceconi C., Fox
K.,
Remme W.J. [et al.]// Cardivasc. Res.-2007.-Vol.73.-P.237-246.5.
Derosa G. Candesartan effect on inflammation in hyperten-
sion/ Derosa G., Maffioli P., Salvadeo S.A. [et al.]//
Hypertens. Res.-2010.-Vol.33.-P.209-213.
6. Dohi Y. Candesartan reduces oxidative stress and
inflamma-tion in patients with essential hypertension/ Dohi Y.,
Ohashi M., Sug-iyama M. [et al.]// Hypertens.
Res.-2003.-Vol.26(9).-P.691-697.
7. Ebinc F.A. The relationship between vascular
endothelialgrowth factor (VEGF) and microalbuminuria in patients
with essentialhypertension// Intern.
Med.-2008.-Vol.47.-P.1511-1516.
8. Farah R. The combined effect of calcium chanell blocker
Ler-canidipine and antioxidants on low-grade systemic inflammation
pa-rameters in essential hypertensive patients/ Farah R.,
Shurts-SwirskiR.// Minerva
Cardioangiol.-2008.-Vol.56.-P.467-476.
9. Fliser D. European Trial on Olmesartan and Pravastatin in
In-flammation and Atherosclerosis (EUTOPIA) investigators.
Antiinflam-matory effects of angiotensin II subtype I receptor
blockade in hyper-tensive patients with microinflammation/ Fliser
D., Buchholz K., HallerH. [et al.]//
Circulation.-2004.-Vol.110.-P.1103-1107.
10. Fujimoto M. An angiotensin II AT1 receptor antagonist,
telm-isartan augments glucose uptake and GLUT4 protein expression
in3T3-L1 adipocytes/ Fujimoto M., Masuzaki H., Tanaca T. [et al.]
//FEBS Letters.-2004. -Vol. 576.-P.492-497.
11. Ibsen H. Reduction in microalbuminuria translates to
reduc-tion of cardiovascular events in hypertensive patients: a
LIFE study/Ibsen H., Olsen M.H., Wachtell K. [et al.]//
Hypertension.-2005.-vol.45.-P.198-202.
12. Iwashima Y. C-reactive protein, left ventricular mass index
andrisk of cardiovascular disease in essential hypertension/
Iwashima Y.,Horio T., Kamide K. [et al.]// Hypertens. Reaserch.-
2007.-Vol. 30(12).-P.1177-1185.
13. Koh K.K. Additive beneficial effects of losartan combined
withsimvastatin in the treatment of hypercholesteremic,
hypertensive pa-tients/ Koh K.K., Quon M.J., Han S.H. [et al.]//
Circulation.-2004.-Vol.110.-P.3687-3692.
14. Kranzhofer R. Angiotensin II activates the
proinflammatorytranscription nuclear factor-kappaB in human
monocytes/ KranzhoferR., Browatski M., Schmidt J. [et al.]//
Biochem. Biophys. Res. Com-mun.-1999.-Vol.257.- P.826-828.
15. Madej A. The effects of 1 month antihypertensive
treatmentwith perindopril, bisoprolol or both on the ex vivo
ability of mono-cytes to secrete inflammatory cytokines/ Madej A.,
Buldak L., BasiakM.
